Cancer really sucks and cancer associated coagulopathy’s are an important piece of the clinical picture that often triggers the use of anticoagulants for VTE prevention so it probably goes beyond VEG-F. It is also a risk factor Leronlimab will step into as part of the clinical trial. That said, the site PI (principal investigator) is ultimately going to make the call on the likely cause of any SAE. Dying from a car accident technically falls into reporting and that is why the PI must make a call…not related to drug, or potentially a signal requiring attention. In this instance the PI understands coagulation issues are properly part of the clinical picture of cancer, especially with certain types of cancer.

For more information: https://publications.ersnet.org/content/errev/28/151/180119